Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial

Amanda Jane Leach, Edward Kim Mulholland, Mathuram Santosham, Paul John Torzillo, Peter McIntyre, Heidi Smith-Vaughan, Nicole Wilson, Beth Arrowsmith, Jemima Beissbarth, Mark D. Chatfield, Victor M. Oguoma, Paul Licciardi, Sue Skull, Ross Andrews, Jonathan Carapetis, Joseph McDonnell, Vicki Krause, Peter Stanley Morris

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)
74 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science